Thats what the American College of Physicians (ACP) is saying in their newly revised clinical recommendations published today in the Annals of Internal Medicine
As a licensed Washington State health insurance broker with over a decade helping Medicare beneficiaries in this state navigate exactly these kinds of questions, I want to give you a straight answer not a marketing pitch
In addition, a large number of clinical studies have shown that GLP-/GIP dual agonists can reduce LFC, VAT, and body weight, and have an improvement effect on both NAFLD and NASH [131,132]
A person should always consult a doctor before starting or switching to a GLP-1
Additionally, in different species, insufficient riboflavin intake can lead to peripheral demyelination (47, 48)